Stock CHGCY CHUGAI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Chugai Pharmaceutical Co., Ltd. OTC Markets

Equities

CHGCY

US1712691039

Delayed OTC Markets
Other stock markets
 20:45:38 28/06/2024 BST 		5-day change 1st Jan Change
17.74 USD -1.93% Intraday chart for Chugai Pharmaceutical Co., Ltd. +10.46% -5.89%
06-24 Japan's Nikkei ends choppy session on stronger note RE
06-24 Japan's Nikkei squeezes out gains in choppy session RE

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Chugai Pharmaceutical : Announcement of a Director Resignation
PU
Chugai Pharmaceutical : All pages, single page [PDF
PU
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO in the UK and Ireland
AQ
Chugai Pharmaceutical - Collaborative Research for Advanced Data Linkage between Electronic Medical Records and Clinical Trial Data Collection System, Expedited Transcription at the Medical Institution and for SDV in the Pharmaceutical Company
AQ
Chugai Pharmaceutical - Maruho Announces Launch of Mitchga Subcutaneous Injection 30mg Vials in Japan
AQ
Chugai Pharmaceutical : Collaborative Research for Advanced Data Linkage between Electronic Medical Records and Clinical Trial Data Collection System Expedited Transcription at the Medical Institution and for SDV in the Pharmaceutical Company
PU
Chugai Pharmaceutical : Personnel Changes
PU
Chugai Pharmaceutical : Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to Provide Information on Detection of Copy Number Alterations of Cancer-Related Genes and bTMB Score
PU
Chugai, NCCH, OMPU and MICIN Start Company-Sponsored Phase I Study in Oncology with a New Decentralized Clinical Trial Structure, Improving access to the clinical trial for patients far from the institution
AQ
Chugai Pharmaceutical : Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
PU
Chugai Announces 2024 1st Quarter Results
AQ
Chugai Pharmaceutical : Q1 Results (Jan-Mar 2024)
PU
Chugai Pharmaceutical : F. Hoffmann-La Roche Announces First Quarter Sales 2024
PU
Chugai Pharmaceutical Co., Ltd. - Positive Phase III Results Showed Vabysmo Improved Vision for the First Time in Japanese in Angioid Streaks
AQ
Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Earthquake off the Eastern Coast of Taiwan
AQ
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanced HR-positive, HER2-negative Breast Cancer
AQ
Chugai Pharmaceutical : Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
PU
Chugai Obtains Regulatory Approval for Vabysmo, the Only Bispecific Antibody in the Ophthalmology Field, for Additional Indication of Macular Edema Associated with Retinal Vein Occlusion
AQ
Chugai Pharmaceutical - Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials
AQ
Chugai Obtains Regulatory Approval for 'Piasky 340mg' for Paroxysmal Nocturnal Hemoglobinuria in Japan
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4519 Stock
  4. CHGCY Stock
  5. News Chugai Pharmaceutical Co., Ltd.
  6. Press Releases